Curis (NASDAQ:CRIS – Get Free Report) announced its quarterly earnings data on Friday. The biotechnology company reported ($4.02) earnings per share for the quarter, topping the consensus estimate of ($6.95) by $2.93, FiscalAI reports.
Curis Price Performance
Shares of NASDAQ CRIS traded down $0.07 during mid-day trading on Friday, reaching $1.80. 470,403 shares of the company’s stock traded hands, compared to its average volume of 266,000. The stock has a market cap of $3.76 million, a P/E ratio of -0.08 and a beta of 3.13. The business has a 50-day simple moving average of $5.84 and a 200 day simple moving average of $11.74. Curis has a 1-year low of $1.54 and a 1-year high of $39.00.
Analyst Ratings Changes
Several research analysts have commented on CRIS shares. Zacks Research downgraded Curis from a “hold” rating to a “strong sell” rating in a report on Tuesday. HC Wainwright restated a “buy” rating and issued a $43.00 target price (up from $17.00) on shares of Curis in a report on Friday, July 24th. Wall Street Zen downgraded Curis to a “strong sell” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus target price of $43.00.
Hedge Funds Weigh In On Curis
Large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC increased its holdings in Curis by 71.8% during the 4th quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 10,586 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Curis in the fourth quarter valued at approximately $26,000. Squarepoint Ops LLC lifted its holdings in shares of Curis by 46.2% in the fourth quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 27,343 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of Curis by 2,883,237.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock valued at $228,000 after buying an additional 230,659 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Curis by 37.3% during the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock valued at $238,000 after buying an additional 65,404 shares during the last quarter. Institutional investors own 29.97% of the company’s stock.
About Curis
Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.
Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.
Read More
- Five stocks we like better than Curis
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.
